Can Wegovy Make You Tired? Fatigue on GLP-1 Therapy

Published May 25, 2026Updated May 27, 2026Last reviewed May 25, 2026

For the broader cluster context, see the semaglutide side effects and safety hub.

Author: HealthRX Editorial Team Medically reviewed by: Dr. Mark Halpern, MD (Internal Medicine, Obesity Medicine) Last clinical review: May 2026

Compounded semaglutide is not FDA-approved. This article is patient education and does not replace consultation with a licensed clinician.

Rachel, 41, a project manager in Columbus, Ohio, messaged her prescribing clinician six weeks into semaglutide therapy with a complaint that didn't match anything she'd read online. "I'm not nauseous. I'm not constipated. I'm just exhausted. Like I pulled an all-nighter, every single day, starting around 2 p.m." Her dose had just been bumped to 1.0 mg. Her food log showed she'd been averaging about 900 calories and 55 grams of protein per day. Within ten days of increasing protein to 110 grams and adding a mid-afternoon snack, the fatigue lifted almost entirely. No dose change required.

That pattern shows up constantly in obesity medicine clinics, and it points to the boring truth about GLP-1 fatigue: the drug usually isn't the direct culprit. The caloric crater it creates is.

This article sits inside the broader Compounded Semaglutide Side Effects and Safety cluster, which is part of the compounded semaglutide pillar guide.

The Short Answer, Then the Longer One

Can Wegovy make you tired? Yes. Fatigue appears in post-marketing reports, and some patients in the STEP program reported low energy during treatment. But "the drug made me tired" and "I'm tired because I'm barely eating" are two different problems with very different fixes, and most patients are dealing with the second one.

Fatigue wasn't one of the headline adverse events in the STEP-1, STEP-3, or STEP-4 trials. Nausea was (roughly 20 percent of STEP-1 participants reported it at some point). Constipation, diarrhea, bloating, reflux, those all showed up at meaningful rates. Fatigue, by contrast, is a nonspecific symptom. It's the clinical equivalent of a check-engine light: it tells you something's off, not what's off.

Compounded semaglutide uses the same active ingredient as Wegovy and Ozempic. It is prepared by a licensed compounding pharmacy under a clinician prescription. It is not FDA-approved. The clinical evidence base for the molecule itself comes from the branded-product trial programs, not from independent randomized trials of compounded preparations.

What Happens to Your Energy Budget on a GLP-1

Think of your daily caloric intake like a household budget. Before semaglutide, you might have been spending $4,000 a month (let's call that 2,400 calories). The drug effectively cuts your appetite so that you're now spending $2,200 (maybe 1,300 calories). Every dollar in that smaller budget has to work harder.

When protein dips below about 0.7 grams per pound of body weight, when hydration drops because you're simply consuming less food volume, when micronutrient density falls because the foods you do eat are nutritionally thin, the body's response is predictable. You feel terrible. And you blame the injection.

Here's the thing: this is a nutritional problem wearing a pharmaceutical costume. The fix is almost always dietary before it's pharmacological.

A patient eating 60 grams of protein per day on 1.0 mg semaglutide who reports fatigue will usually feel markedly better at 100 grams per day. No medication adjustment. No lab workup. Just more chicken and Greek yogurt.

When Fatigue Actually Signals Something Else

Not every case resolves with a protein shake. If basic intake corrections don't move the needle within a couple of weeks, the next step is labwork. The standard screen includes:

Iron and ferritin (especially in menstruating women, who are overrepresented in GLP-1 prescribing)
B12 (long-term GI changes can affect absorption)
Thyroid function (TSH, free T4)
Renal function (BUN, creatinine)
Fasting glucose or A1c if the patient has diabetes (mild hypoglycemia presents as fatigue, not just shakiness)

Persistent fatigue beyond six weeks at a stable dose, with adequate nutrition and normal labs, is worth a real conversation with the prescriber. It may warrant a dose reduction or a longer hold at the current dose before escalating.

My honest clinical opinion: most patients never get to this step because the protein and hydration fix works. But "most" isn't "all," and the patients it doesn't work for deserve a thorough evaluation, not reassurance.

The Broader Safety Picture (Because Context Matters)

The published trial record for semaglutide is one of the more comprehensive safety datasets in obesity medicine. Across STEP-1, STEP-3, STEP-4, SUSTAIN-6, LEADER, and SELECT, gastrointestinal events dominated the adverse effect profile, and serious adverse events were uncommon.

A few things worth knowing:

Pancreatitis was reported in a small fraction of patients across these trials. The rate did not differ significantly between active drug and placebo arms in SELECT or LEADER, though individual cases always warrant attention.
The label for Wegovy and Ozempic carries a boxed warning regarding thyroid C-cell tumors based on rodent data. Human evidence for that risk has not materialized at population scale in the large outcome trials. Most prescribers screen for personal or family history of medullary thyroid carcinoma or MEN2 before prescribing.
Nausea follows a predictable dose-related pattern: it appears at or shortly after a dose increase and typically improves within one to two weeks. About 20 percent of STEP-1 participants reported it at some point, though severe nausea was considerably less common.

The side effect profile of compounded semaglutide programs mirrors what was reported for the branded products, which makes pharmacological sense given the identical active ingredient. The regulatory status, oversight, and supply chain for compounded preparations are distinct from branded products. That distinction matters for quality assurance, but the molecular biology doesn't change.

Practical Mitigations That Actually Help

The four most reliable interventions for GI tolerability (and by extension, for the downstream fatigue that poor tolerability causes):

Small, slow meals. Your stomach is getting satiety signals faster now. Respect them.
Lower-fat content, especially in the first two weeks after a dose increase. High-fat meals sit longer and amplify nausea.
Adequate hydration. When food volume drops, fluid intake needs to come from somewhere else. Aim for at least 64 ounces daily; more if you're active.
Avoid very rich or fried foods during dose escalation. This one feels obvious until you forget it at a birthday dinner.

Anti-nausea medication is a routine tool in the clinical toolkit. It's appropriate for some patients and should be viewed as a pragmatic bridge, not a failure.

Misconceptions That Keep Circulating

"If I feel worse, the drug must be working harder." Trial data don't support this. STEP-1 and STEP-3 both showed meaningful weight loss in patients with minimal side effects and in patients with more pronounced GI symptoms. Side effect intensity does not predict response.

"Compounded semaglutide is the same as Wegovy." Same molecule. Different regulatory category. Compounding pharmacies operate under a different framework with different oversight. Compounded preparations are not FDA-approved. That's a legal and regulatory fact, not a quality judgment, but it's a distinction patients should understand.

"The medication does the whole job." STEP-3, which paired semaglutide with a structured lifestyle intervention, produced greater mean weight loss than STEP-1, which used medication alone. Lifestyle is additive. It's not optional for durable results.

"If I stop, I'll be fine." STEP-4 documented partial weight regain over 48 weeks after switching from active drug to placebo at week 20. This isn't a personal failing. Weight regulation is chronic biology. It trends back toward baseline without ongoing intervention, the same way blood pressure returns to pre-treatment levels when you stop an antihypertensive.

When to Pick Up the Phone

The threshold for contacting your prescriber should be lower than most patients assume. Call promptly for:

Vomiting lasting more than one day
Severe upper abdominal pain, especially if it radiates to the back
Signs of dehydration (dark urine, dizziness on standing, dry mouth that won't quit)
Jaundice (yellowing of skin or eyes)
Persistent severe headache or vision changes

Most GI side effects don't rise to this level and can be managed with a dose hold or symptomatic care. But when in doubt, call. That's what the clinician relationship is for.

Adjacent Reading

For a broader treatment of the molecule, the regulatory pathway, the 503A and 503B compounding framework, and the full clinical evidence base, the compounded semaglutide pillar guide is the primary reference on this site.

Frequently Asked Questions

Are the side effects of compounded semaglutide different from Wegovy or Ozempic?

The active ingredient is the same. The side effect profile reported in compounded semaglutide programs mirrors what was reported in SUSTAIN, STEP-1, and STEP-3 for the branded products. Compounded preparations are not FDA-approved and have not been independently studied in the same way.

When should a side effect trigger a call to the prescriber?

Severe abdominal pain, persistent vomiting, signs of dehydration, jaundice, or vision changes are reasons to contact the prescribing clinician promptly. Most GI side effects are dose-related and improve with adjustment.

Do side effects predict effectiveness?

There is no reliable evidence that nausea or other GI side effects predict greater weight loss. Trial data show meaningful weight loss in patients with minimal side effects as well as those with more pronounced symptoms.

How long does fatigue typically last on semaglutide?

For most patients, fatigue that's driven by inadequate caloric or protein intake improves within one to two weeks of dietary correction. Fatigue related to dose escalation usually settles within two to three weeks at a stable dose. Fatigue persisting beyond six weeks at the same dose warrants clinical evaluation.

Should I lower my dose if I feel tired?

Not as a first step. Check your protein intake, hydration, and overall caloric floor first. If those are adequate and fatigue persists, a dose hold or reduction is reasonable, but that's a decision to make with your prescribing clinician.

Compliance and Authorship

This article references the STEP-1, STEP-3, STEP-4, SUSTAIN, SELECT, and LEADER clinical trial programs where appropriate. It is intended as patient education and does not replace consultation with a licensed clinician.